Literature DB >> 25609866

Management of hypereosinophilia in tropical settings.

Arjun Datt Law1, Subhash Chander Varma2.   

Abstract

Hypereosinophilia includes a group of commonly encountered clinical situations with symptoms ranging from mild and clinically innocuous to devastating presentations with high morbidity and mortality. The presentations and complications can be easily missed if the clinician is unaware of the diverse entities responsible for hypereosinophilia. The hypereosinophilic syndromes encompass entities that are associated with varying degrees of organ dysfunction either directly due to eosinophilic infiltration or as a result of substances secreted by the eosinophils. These conditions may be neoplastic or reactive in aetiology and a diligent search for secondary causes is essential. Evaluation and management algorithms in the tropical setting and in developing countries may differ from elsewhere. A review of hypereosinophilia and hypereosinophilic syndromes is presented with a diagnostic and therapeutic decision making algorithm modified for use in the tropical setting.

Entities:  

Keywords:  Eosinophilia; Hypereosinophilia; Hypereosinophilic syndrome

Year:  2014        PMID: 25609866      PMCID: PMC4297847          DOI: 10.1016/j.mjafi.2014.11.008

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  29 in total

Review 1.  Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis.

Authors:  J H Butterfield
Journal:  Acta Haematol       Date:  2005       Impact factor: 2.195

2.  Catastrophic thrombosis in idiopathic hypereosinophilic syndrome.

Authors:  Sophie Todd; Claire Hemmaway; Zoltan Nagy
Journal:  Br J Haematol       Date:  2014-01-24       Impact factor: 6.998

3.  Acute myeloid leukemia with marrow hypereosinophilia and chromosome 16.

Authors:  P Bernard; D Dachary; F Lacombe; M R Boisseau; B David; J Reiffers; A Broustet
Journal:  Blood       Date:  1984-01       Impact factor: 22.113

4.  Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

Authors:  Jelena V Jovanovic; Joannah Score; Katherine Waghorn; Daniela Cilloni; Enrico Gottardi; Georgia Metzgeroth; Philipp Erben; Helena Popp; Christoph Walz; Andreas Hochhaus; Catherine Roche-Lestienne; Claude Preudhomme; Ellen Solomon; Jane Apperley; Michela Rondoni; Emanuela Ottaviani; Giovanni Martinelli; Finella Brito-Babapulle; Giuseppe Saglio; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Reiter; David Grimwade
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

5.  Cobalamin (vitamin B12) and B12 binding proteins in hypereosinophilic syndromes and secondary eosinophilia.

Authors:  J Zittoun; J P Farcet; J Marquet; C Sultan; R Zittoun
Journal:  Blood       Date:  1984-04       Impact factor: 22.113

Review 6.  Eosinophilia and thrombosis in parasitic diseases: an overview.

Authors:  Paul R J Ames; Giuseppina Aloj; Fabrizio Gentile
Journal:  Clin Appl Thromb Hemost       Date:  2009-10-14       Impact factor: 2.389

Review 7.  Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome.

Authors:  Naoto T Ueno; Athanasios Anagnostopoulos; Gabriela Rondón; Richard E Champlin; N Mikhailova; O S Pankratova; L S Zoubarovskaya; E V Semenova; B V Afanasyev; Susan O'Brien; Michael Andreeff; Andrey Y Zaritskey
Journal:  Br J Haematol       Date:  2002-10       Impact factor: 6.998

8.  Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions.

Authors:  Garry M Walsh
Journal:  Curr Opin Mol Ther       Date:  2009-06

9.  Bone marrow eosinophilia as a prognostic indicator in acute myelogenous leukemia with 8;21 translocation.

Authors:  M Hagihara; H Miyachi; H Kobayashi; T Ogawa
Journal:  Int J Hematol       Date:  1992-04       Impact factor: 2.490

10.  The association of eosinophilia with lymphoblastic leukaemia or lymphoma: a study of seven patients.

Authors:  D Catovsky; C Bernasconi; P J Verdonck; A Postma; J Hows; A van der Does-van den Berg; J K Rees; G Castelli; E Morra; D A Galton
Journal:  Br J Haematol       Date:  1980-08       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.